Matt Zuga - 06 Jul 2021 Form 4 Insider Report for Acumen Pharmaceuticals, Inc. (ABOS)

Role: Chief Financial Officer
Signature: /s/ Katherine Denby, Attorney-in-Fact
Issuer symbol: ABOS
Transactions as of: 06 Jul 2021
Net transactions value: $0
Form type: 4
Filing time: 08 Jul 2021, 18:18:23 UTC
Previous filing: 30 Jun 2021
Next filing: 21 Jan 2022
SEC: View on sec.gov

Transactions Table

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Ownership	Footnotes
transaction	ABOS	Common Stock	Conversion of derivative security		+26,187			26,187	06 Jul 2021	Direct	F1

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type	Sym	Class	Transaction	Value $	Shares	Change %	* Price $	Shares After	Date	Underlying Class	Amount	Exercise Price	Ownership	Footnotes
transaction	ABOS	Series A-1 Preferred Stock	Conversion of derivative security		-15,659	-50%		15,659	06 Jul 2021	Common Stock	15,659		Direct	F1
transaction	ABOS	Series B Preferred Stock	Conversion of derivative security		-10,528	-50%		10,528	06 Jul 2021	Common Stock	10,528		Direct	F1

* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id	Content
F1	On July 6, 2021, each share of Series A-1 Convertible Preferred Stock and Series B Convertible Preferred Stock (collectively, the "Preferred Stock") converted into Common Stock on a one-for-one basis without payment of further consideration upon closing of the initial public offering of the Issuer's common stock. The shares had no expiration date.